GLUL and Stroke: Interventions designed to alter key enzyme levels in vivo (e.g., MSO administration to inhibit glutamine synthetase; administration of AspAT) and thereby diminish CNS glutamate levels have recently shown promise in animal models of ALS and stroke, respectively.